/PRNewswire/ Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and.
/PRNewswire/ Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and.
Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
- Significant partnership agreement with the world-renowned International Institute of Molecular and Cell Biology in Warsaw (IIMCB) to accelerate the strategic development of OncoArendi's small
- Option to in-license and develop small molecule leads against a novel target for the treatment of fibrotic diseases - Strengthens pipeline and reinforces OncoArendi's strategic focus